Capricor Therapeutics (CAPR) Non-Current Deffered Revenue (2014 - 2023)

Capricor Therapeutics (CAPR) recorded quarterly Non-Current Deffered Revenue of $953470.0 in Q3 2023, down 70.5% quarter-over-quarter from $3.2 million in Q2 2023, and down 90.27% on a YoY basis from $9.8 million in Q3 2022.

Capricor Therapeutics (CAPR) Non-Current Deffered Revenue (2014 - 2023) Analysis & Trends

Capricor Therapeutics' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $953470.0 for Q3 2023.

  • In Q3 2023, Non-Current Deffered Revenue fell 90.27% year-over-year to $953470.0; the TTM figure through Sep 2023 stood at $953470.0 (down 90.27% YoY), while the FY2022 annual figure was $9.5 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue was $953470.0 for Q3 2023 at Capricor Therapeutics, down from $3.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $20.3 million in Q1 2022 to a low of $953470.0 in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 Capricor Therapeutics 1.53 Bn 1.26 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2023 953,470.00
Jun 30, 2023 3.23 Mn
Mar 31, 2023 5.45 Mn
Dec 31, 2022 9.47 Mn
Sep 30, 2022 9.80 Mn
Jun 30, 2022 14.30 Mn
Mar 31, 2022 20.30 Mn
Dec 31, 2015 911,458.00
Sep 30, 2015 1.82 Mn
Jun 30, 2015 2.73 Mn
Mar 31, 2015 3.12 Mn
Dec 31, 2014 4.17 Mn
Sep 30, 2014 5.21 Mn
Jun 30, 2014 6.25 Mn
Mar 31, 2014 7.29 Mn